OncLive SOSS

Authors

Thomas Powles, MD, MBBS, MRCP

Latest:

Dr Powles on Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Thomas Prebet, MD, PhD.

Thomas Prebet, MD, PhD, Yale Cancer Center

Thomas R. Barr, MBA

Latest:

Performance Metrics in Oncology

In 2011, the Medicare Electronic Health Record Incentive Program began paying physicians and hospitals for the measurement and reporting of performance metrics through the utilization of certified electronic medical record software.

Thomas R. McLean

Latest:

Metadata: An Orwellian Big Brother within Electronic Medical Records

Consider this hypothetical situation: A patient with new onset of a major depression is evaluated by a physician who has found no evidence of suicidal ideation.

Thomas S. Uldrick, MD

Latest:

Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCD

Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.

Thomas Seufferlein, MD, University of Ulm

Thomas W. Dubensky, PhD

Latest:

Thomas Dubensky on How ADU-S100 Activates STING

Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

Thomas W. Flaig, MD

Latest:

Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder Cancer

Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Thomas W. LeBlanc, MD

Latest:

Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Thomas Wright, MD

Latest:

HPV Test With Genotyping Tops Cervical Cancer Screening Strategies

Cervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.

Tian Zhang, MD, MHS, UT Southwestern Medical Center

Latest:

Dr Zhang on Topics of Ongoing Debate Within Prostate Cancer

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Tian Zhang, MD, Duke Cancer Center

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

Tianhong Li, MD, PhD

Latest:

Dr. Li Reviews Afatinib Data From the LUX-Lung 3 Trial

Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

Ticiana A. Leal, MD

Ticiana A. Leal, MD, is an associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia; as well as medical director of the Clinical Trials Office and leader of the Lung Cancer Disease Team at the Winship Cancer Institute of Emory University

Latest:

Dr Leal on Clinical Considerations Surrounding the Diagnosis of LEMS in Patients With Lung Cancer

Ticiana Leal, MD, discusses clinical considerations surrounding the diagnosis of LEMS in patients with lung cancer.

Ticiana A. Leal, MD, University of Wisconsin School of Medicine

Ticiana Leal, MD, University of Wisconsin-Madison

Latest:

Updates in Systemic Therapy for Non-Metastatic Lung Cancer

Tiffany A. Traina, MD

Latest:

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial

Tiffany Traina, MD, FASCO, highlights results from the phase 3 TROPION-Breast02 trial showing that datopotamab deruxtecan significantly improved progression-free and overall survival versus chemotherapy in patients with previously untreated triple-negative breast cancer who were not eligible for immunotherapy.

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

Latest:

Addressing Treatment Gaps in HER2+ MBC

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Tiffany Traina, MD, Memorial Sloan Kettering Cancer Center

Latest:

Consequences of Chemotherapy-Induced Neutropenia

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.